AbCellera’s menopause medicine ‘sets new efficacy bar’ for hot flashes
AbCellera’s menopause medicine ‘sets new efficacy bar’ for hot flashes
AbCellera
Discovers and develops antibody therapeutics using high-throughput single cell analysis and microfluidic platforms for complex transmembrane proteins, bispecifics, and ADCs. Reported strong menopause medicine efficacy data (Phase 2) in August 2026.
Company Info
Sector:Antibody Discovery / Platform
Headquarters:Vancouver, British Columbia, Canada
Founded:2012
Website:www.abcellera.com/
Upcoming Milestones & Key Dates
2026 Q4
Clinical Data
Menopause Phase 2 full data readout
2027
Clinical Trial
Potential Phase 3 start for menopause candidate
Clinical Development Pipeline
ABCL575 (partnered)
Target: OX40 ligand antibodyABCL635
Target: Neurokinin 3 receptor (NK3R)ABCL2771
Target: UndisclosedRecent News
Leadership Team
Carl Hansen
CEO & Chairman
Tryfonas Vlahakos
Chief Technology Officer
Veronique Lecault
Chief Operating Officer